Wednesday, July 8, 2026

Patent intelligence · US

US 9511015

Methods and formulations for treating sialic acid deficiencies

granted A61KA61K31/335A61K31/35A61K31/7012
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 23
Patent details — US 9511015
Jurisdiction
US
Status
granted
Grant date
Dec 6, 2016
Expiration
Dec 1, 2036
Claims
16
CPC classes
A61K, A61K31/335, A61K31/35, A61K31/7012
View on Google Patents ↗

Quick answer

US 9511015 (Methods and formulations for treating sialic acid deficiencies) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Dec 6, 2016. Expires Dec 1, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/335, A61K31/35, A61K31/7012, A61K9/0002, A61K9/0053

More from Ultragenyx Pharmaceutical Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12358976

    Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d

    Ultragenyx Pharmaceutical Inc. · Expires Jul 10, 2045

    granted
  2. US 12338450

    Gene therapy constructs for treating Wilson disease

    Ultragenyx Pharmaceutical Inc. · Expires Jun 19, 2045

    granted
  3. US 11944658

    Methods of heat inactivation of adenovirus

    Ultragenyx Pharmaceutical Inc. · Expires Mar 28, 2044

    granted
  4. US 11771748

    Methods for treating tumor-induced osteomalacia

    Ultragenyx Pharmaceutical Inc. · Expires Sep 28, 2043

    granted
  5. US 11753369

    Creatine prodrugs, compositions and methods of use thereof

    Ultragenyx Pharmaceutical Inc. · Expires Sep 7, 2043

    granted
  6. US 11377643

    Therapeutics for glycogen storage disease type III

    Ultragenyx Pharmaceutical Inc. · Expires Jun 30, 2042

    granted
  7. US 11332438

    Creatine prodrugs, compositions and methods of use thereof

    Ultragenyx Pharmaceutical Inc. · Expires May 12, 2042

    granted
  8. US 11202822

    Methods for treating hypophosphatemic disorders

    Ultragenyx Pharmaceutical Inc. · Expires Dec 16, 2041

    granted

Frequently asked questions

What is US patent 9511015?

US 9511015 (Methods and formulations for treating sialic acid deficiencies) is held by Ultragenyx Pharmaceutical Inc.. Status: granted. Granted Dec 6, 2016. Expires Dec 1, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9511015?

Ultragenyx Pharmaceutical Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.

When does US 9511015 expire?

Our index shows an expiration date of Dec 1, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.